RECIP 1.0 + PSA for response assessment in mCRPC patients treated with ²²⁵Ac / ¹⁷⁷Lu PSMA combination therapy.

ABSTRACT:

Background

Targeted alpha therapy (TAT) with ²²⁵Ac has shown promising results in metastatic castration-resistant prostate cancer (mCRPC) patients pre-treated with [¹⁷⁷Lu]Lu-PSMA radioligand therapy (RLT). A combination treatment regimen adding ¹⁷⁷Lu to decreased ²²⁵Ac activities may improve toxicity profile while maintaining sufficient anti-tumor effect. We therefore evaluated clinical and image-based response parameters in patients treated with ²²⁵Ac-/¹⁷⁷Lu-PSMA combination therapies (ALCT).

Results

Complete response (RECIP-CR), partial response (RECIP-PR), stable disease (RECIP-SD), progressive disease (RECIP-PD) according to RECIP 1.0 was observed in 0/25 (0%), 12/25 (48%), 9/25 (36%) and 4/25 (16%) patien

SUBMITTER: Sheikh GT 

PROVIDER: S-EPMC11880445 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature